Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of JNJ-64457744 in Healthy and Chronic Hepatitis B Participants
NCT05423106Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-64457744 in Chronic Hepatitis B (CHB) (7 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Serious Adverse Events, Number of Participants With Clinical Laboratory Abnormalities up to 8 weeks and 2 more. Started Jul 2022; status: terminated.
02
Drugs
JNJ-64457744
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05423106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05423106.